Advertisement

Archives of Osteoporosis

, 13:15 | Cite as

Epidemiology and correlates of osteoporotic fractures among type 2 diabetic patients

  • Inbal GoldshteinEmail author
  • Allison Martin Nguyen
  • Anne E. dePapp
  • Sofia Ish-Shalom
  • Julie M. Chandler
  • Gabriel Chodick
  • Varda Shalev
Original Article

Abstract

Summary

This study analyzed data on 87,224 osteoporotic patients with up to 18 years of computerized medical history. Patients with osteoporosis and type 2 diabetes had higher bone density yet more fractures than non-diabetic osteoporotic patients. Fracture incidence among the diabetic patients was associated with retinopathy and cardiovascular disease, but not with diabetes duration.

Purpose

Little is known about the association between type 2 diabetes mellitus (T2DM) and fragility fractures or the mechanism(s) involved. We examined fracture correlates among T2DM patients with osteoporosis.

Methods

We used electronic health records of an osteoporosis (OP) registry cross-linked with a diabetes registry of a large payer provider healthcare organization in Israel. A cross-sectional analysis compared osteoporosis patients with and without T2DM, and a longitudinal Cox proportional hazard regression was used to identify incident fracture correlates.

Results

As of December 2015 a total of 87,224 current OP patients were identified, of whom 15,700 (18%) had T2DM. The T2DM OP patients were characterized by older age (mean 74.6 vs. 69.5), more males (20.3 vs. 14.0%), and a higher rate of chronic comorbidities compared to OP without diabetes. All major OP fractures (hip, spine, humerus, and forearm) were significantly more prevalent among T2DM OP patients (44 vs. 32%), with an overall age-standardized ratio of 1.22 (95% CI 1.19 to 1.25) and 1.15 (95% CI 1.10 to 1.21) for females and males respectively. The average T-scores were higher (femur neck − 1.8 vs. − 1.9, total hip − 1.2 vs. − 1.6, and vertebrae − 1.3 vs. − 1.7) for the T2DM OP patients compared to the non-T2DM OP patients. Among women with coexisting T2DM and osteoporosis (n = 10,812), fracture incidence was significantly associated with retinopathy (HR = 1.24, 95% CI 1.05 to 1.47) and cardiovascular disease (HR = 1.22, 95% CI 1.10 to 1.36) after controlling for age, bone mineral density T-score, rheumatoid arthritis, glucocorticoids, alcohol, and smoking).

Conclusion

This large population-based study confirms the higher fracture risk of osteoporotic patients with T2DM, as compared to osteoporotic patients without T2DM, despite higher bone mineral density levels. The presence of micro- and macrovascular disease appears to increase this risk.

Keywords

Osteoporosis Type 2 diabetes mellitus Fracture Complications 

Notes

Acknowledgements

We are grateful for the assistance of Mrs. Racheli Katz and Cheli Meltzer Cohen in data extraction and Mrs. Esther Eshkol in language editing.

Compliance with ethical standards

Conflicts of interest

Sofia Ish-Shalom has received research grants and consulting, advisory board, lecture fees, and any combination of the three from Merck Sharp & Dohme, Eli Lilly, Enterabio, GlaxoSmithKline, and Novartis. Anne E. dePapp and Allison Martin Nguyen are employees of Merck & Co., Inc. Julie Chandler was an employee of Merck & Co. at the time of this analysis and manuscript preparation. Inbal Goldshtein, Varda Shalev, and Gabriel Chodick declare that they have no conflict of interest.

References

  1. 1.
    Ishii S, Cauley JA, Crandall CJ, Srikanthan P, Greendale GA, Huang MH, Danielson ME, Karlamangla AS (2012) Diabetes and femoral neck strength: findings from the hip strength across the menopausal transition study. J Clin Endocrinol Metab 97:190–197CrossRefGoogle Scholar
  2. 2.
    Kurra S, Siris E (2011) Diabetes and bone health: the relationship between diabetes and osteoporosis-associated fractures. Diabetes Metab Res Rev 27:430–435CrossRefGoogle Scholar
  3. 3.
    Hamann C, Kirschner S, Gunther KP, Hofbauer LC (2012) Bone, sweet bone—osteoporotic fractures in diabetes mellitus. Nat Rev Endocrinol 8:297–305CrossRefGoogle Scholar
  4. 4.
    Giangregorio LM, Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA (2012) FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 27:301–308CrossRefGoogle Scholar
  5. 5.
    Jackuliak P, Payer J (2014) Osteoporosis, fractures, and diabetes. Int J Endocrinol 2014:820615CrossRefGoogle Scholar
  6. 6.
    Tuominen JT, Impivaara O, Puukka P, Rönnemaa T (1999) Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care 22:1196–1200CrossRefGoogle Scholar
  7. 7.
    Botella Martinez S, Varo Cenarruzabeitia N, Escalada San Martin J, Calleja Canelas A (2016) The diabetic paradox: bone mineral density and fracture in type 2 diabetes. Endocrinol Nutr 63:495–501CrossRefGoogle Scholar
  8. 8.
    Goldshtein I, Gerber Y, Ish-Shalom S, Leshno M (2018) Fracture risk assessment with FRAX using real-world data in a population-based cohort from Israel. Am J Epidemiol 187:94–102CrossRefGoogle Scholar
  9. 9.
    Vogt MT, Cauley JA, Kuller LH, Nevitt MC (1997) Bone mineral density and blood flow to the lower extremities: the study of osteoporotic fractures. J Bone Miner Res 12:283–289CrossRefGoogle Scholar
  10. 10.
    Sibai AM, Costanian C, Tohme R, Assaad S, Hwalla N (2013) Physical activity in adults with and without diabetes: from the ‘high-risk’ approach to the ‘population-based’ approach of prevention. BMC Public Health 13:1002CrossRefGoogle Scholar
  11. 11.
    Chastin SF, Mandrichenko O, Helbostadt JL, Skelton DA (2014) Associations between objectively-measured sedentary behaviour and physical activity with bone mineral density in adults and older adults, the NHANES study. Bone 64:254–262CrossRefGoogle Scholar
  12. 12.
    Lord SR, Dayhew J (2001) Visual risk factors for falls in older people. J Am Geriatr Soc 49:508–515CrossRefGoogle Scholar
  13. 13.
    Palermo A, D’Onofrio L, Eastell R, Schwartz AV, Pozzilli P, Napoli N (2015) Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review. Osteoporos Int 26:2073–2089CrossRefGoogle Scholar
  14. 14.
    Janghorbani M, Van Dam RM, Willett WC, Hu FB (2007) Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 166:495–505CrossRefGoogle Scholar
  15. 15.
    Leidig-Bruckner G, Grobholz S, Bruckner T, Scheidt-Nave C, Nawroth P, Schneider JG (2014) Prevalence and determinants of osteoporosis in patients with type 1 and type 2 diabetes mellitus. BMC Endocr Disord 14:33CrossRefGoogle Scholar
  16. 16.
    Hofbauer LC, Brueck CC, Singh SK, Dobnig H (2007) Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 22:1317–1328CrossRefGoogle Scholar
  17. 17.
    Leidig-Bruckner G, Ziegler R (2001) Diabetes mellitus a risk for osteoporosis? Exp Clin Endocrinol Diabetes 109(Suppl 2):S493–S514CrossRefGoogle Scholar
  18. 18.
    de Liefde II, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA (2005) Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam study. Osteoporos Int 16:1713–1720CrossRefGoogle Scholar
  19. 19.
    Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397CrossRefGoogle Scholar
  20. 20.
    Chodick G, Heymann AD, Shalev V, Kookia E (2003) The epidemiology of diabetes in a large Israeli HMO. Eur J Epidemiol 18:1143–1146CrossRefGoogle Scholar
  21. 21.
    Shalev V, Chodick G, Goren I, Silber H, Kokia E, Heymann AD (2011) The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization. Int J Cardiol 152:345–349CrossRefGoogle Scholar
  22. 22.
    Goldshtein I, Chandler J, Shalev V et al (2015) Osteoporosis in the community: findings from a novel computerized registry in a large health organization in Israel. J Aging Res Clin Practice 4:59–65Google Scholar
  23. 23.
    Sella T, Shoshan A, Goren I, Shalev V, Blumenfeld O, Laron Z, Chodick G (2011) A retrospective study of the incidence of diagnosed type 1 diabetes among children and adolescents in a large health organization in Israel, 2000–2008. Diabet Med 28:48–53CrossRefGoogle Scholar
  24. 24.
    Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ (2008) Translating the A1C assay into estimated average glucose values. Diabetes Care 31:1473–1478CrossRefGoogle Scholar
  25. 25.
    Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G, for the A Diabetes Outcome Progression Trial (ADOPT) Study Group (2008) Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31:845–851CrossRefGoogle Scholar
  26. 26.
    Aubert RE, Herrera V, Chen W, Haffner SM, Pendergrass M (2010) Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab 12:716–721CrossRefGoogle Scholar
  27. 27.
    Heo M, Faith MS, Pietrobelli A (2002) Resistance to change of adulthood body mass index. Int J Obes Relat Metab Disord 26:1404–1405CrossRefGoogle Scholar
  28. 28.
    Health UDo, Services H (2012) Preventing tobacco use among youth and young adults: a report of the surgeon general. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA, p 3Google Scholar
  29. 29.
    Edwards R, Carter K, Peace J, Blakely T (2013) An examination of smoking initiation rates by age: results from a large longitudinal study in New Zealand. Aust N Z J Public Health 37:516–519CrossRefGoogle Scholar
  30. 30.
    Cohen J (1977) Statistical power analysis for the behavioral sciences, chapter 2: the t test for means. Academic Press, Inc., TorontoGoogle Scholar
  31. 31.
    Team RC (2014) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. 2013Google Scholar
  32. 32.
    Keegan TH, Schwartz AV, Bauer DC, Sellmeyer DE, Kelsey JL (2004) Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. Diabetes Care 27:1547–1553CrossRefGoogle Scholar
  33. 33.
    Johnell O, Kanis JA, Black DM, Balogh A, Poor G, Sarkar S, Zhou C, Pavo I (2004) Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) study. J Bone Miner Res 19:764–772CrossRefGoogle Scholar
  34. 34.
    Dede AD, Tournis S, Dontas I, Trovas G (2014) Type 2 diabetes mellitus and fracture risk. Metabolism 63:1480–1490CrossRefGoogle Scholar
  35. 35.
    Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int 18:427–444CrossRefGoogle Scholar
  36. 36.
    Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR, Study of Osteoporotic Features Research Group (2001) Older women with diabetes have an increased risk of fracture: a prospective study. The Journal of Clinical Endocrinology & Metabolism 86:32–38CrossRefGoogle Scholar
  37. 37.
    Miao J, Brismar K, Nyren O, Ugarph-Morawski A, Ye W (2005) Elevated hip fracture risk in type 1 diabetic patients: a population-based cohort study in Sweden. Diabetes Care 28:2850–2855CrossRefGoogle Scholar
  38. 38.
    Shanbhogue VV, Hansen S, Frost M, Jørgensen NR, Hermann AP, Henriksen JE, Brixen K (2016) Compromised cortical bone compartment in type 2 diabetes mellitus patients with microvascular disease. Eur J Endocrinol 174:115–124CrossRefGoogle Scholar
  39. 39.
    Leslie WD, Morin SN, Majumdar SR, Lix LM (2018) Effects of obesity and diabetes on rate of bone density loss. Osteoporos Int 29:61–67CrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2018

Authors and Affiliations

  • Inbal Goldshtein
    • 1
    Email author
  • Allison Martin Nguyen
    • 2
  • Anne E. dePapp
    • 2
  • Sofia Ish-Shalom
    • 3
  • Julie M. Chandler
    • 2
  • Gabriel Chodick
    • 1
  • Varda Shalev
    • 1
  1. 1.Epidemiology & Database Research UnitMaccabi Healthcare ServicesTel AvivIsrael
  2. 2.Merck & Co Inc.North WalesUSA
  3. 3.Endocrine ClinicElisha HospitalHaifaIsrael

Personalised recommendations